Literature DB >> 8593018

Pharmacokinetics of intravenously administered isepamicin in men.

C C Lin1, E Radwanski, C Korduba, M Cayen, M Affrime.   

Abstract

The pharmacokinetics of isepamicin, a broad-spectrum aminoglycoside antibiotic, were studied in men after intravenous administration. Three groups of six volunteers received isepamicin for 10 consecutive days by 0.5-h intravenous infusions at respective dosages of 7.5 mg/kg of body weight once daily, 7.5 mg/kg twice daily, and 15 mg/kg once daily. Levels of isepamicin in plasma and urine were determined by a specific high-performance liquid chromatography method. For all three groups, steady-state concentrations of the drug in plasma were attained with the first dose. The area under the concentration-time curve for plasma and urinary drug excretion were dose proportional. A half-life ranging from 2.0 to 2.5 h was independent of the dosage regimen. Isepamicin excreted in urine over 24 h accounted for about 100% of the dose. The results show that the pharmacokinetics of isepamicin are linear with these dosage regimens. The drug does not accumulate upon multiple dosing, undergoes no detectable biotransformation, and is cleared solely by urinary excretion.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593018      PMCID: PMC163028          DOI: 10.1128/AAC.39.12.2774

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  1-N HAPA gentamicin B, a new aminoglycoside active against gentamicin resistant isolates--activity compared to other aminoglycosides.

Authors:  H C Neu; K P Fu
Journal:  J Antibiot (Tokyo)       Date:  1978-05       Impact factor: 2.649

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

3.  Comparative pharmacokinetics of tobramycin and gentamicin.

Authors:  C Regamey; R C Gordon; W M Kirby
Journal:  Clin Pharmacol Ther       Date:  1973 May-Jun       Impact factor: 6.875

4.  Comparison of netilmicin and gentamicin pharmacokinetics in humans.

Authors:  M Chung; R Costello; S Symchowicz
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

5.  Kinetics of netilmicin in man.

Authors:  J C Pechere; R Dugal; M M Pechere
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

6.  Pharmacokinetic study of sisomicin in humans.

Authors:  M Chung; J J Schrogie; S Symchowicz
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

7.  Netilmicin and gentamicin multidose kinetics in normal subjects.

Authors:  O L Laskin; J A Longstreth; C R Smith; P S Lietman
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

8.  Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers.

Authors:  N E Winslade; M H Adelman; E J Evans; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

9.  Kinetics of netilmicin and gentamicin.

Authors:  J A Jahre; K P Fu; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

10.  Appearance of amikacin and tobramycin resistance due to 4'-aminoglycoside nucleotidyltransferase [ANT(4')-II] in gram-negative pathogens.

Authors:  G A Jacoby; M J Blaser; P Santanam; H Hächler; F H Kayser; R S Hare; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

View more
  2 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of isepamicin.

Authors:  M Tod; C Padoin; O Petitjean
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

2.  Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.

Authors:  D J Demczar; A N Nafziger; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.